Abstract
Purpose
Dextranomer/hyaluronic acid (Deflux®) has been increasingly used for the treatment of vesicoureteral reflux (VUR). Experience has shown that injecting more volume of material is necessary to achieve greater success. We evaluate trends in the number of vials being used to treat VUR using a multi-institutional database and data from patients treated at our own institution.
Methods
Children of age 0–19 years in the Pediatric Health Information System (PHIS) database from 2003 to 2008 were extracted with a VUR diagnosis (ICD-9 593.7x) and subureteric injection procedure code (CPT 52327). We identified children with reflux treated with endoscopic injection at Seattle Children’s Hospital from 2005 to 2008. Hospital trends of the number of vials used were evaluated using multivariate linear regression.
Results
From 2003 to 2008, we identified 4,078 endoscopic injection procedures in PHIS. There was a 33% increase in the average number of vials used per patient (p < 0.0001) with more than a threefold increase in the number of patients receiving three or more vials per procedure. All institutions increased the average vials used per patient with the most pronounced increase at the highest-volume centers. These trends were also present in the 186 children treated at our own institution.
Conclusion
Over the study period there was an increase in the number of vials of dextranomer/hyaluronic acid being used per patient to treat children with VUR. This practice may improve success rates but will increase the cost of treatment due to the inherent expense of the material.
Similar content being viewed by others
Abbreviations
- VUR:
-
Vesicoureteral reflux
- PHIS:
-
Pediatric health information system
References
Wheeler D, Vimalachandra D, Hodson EM, Roy LP, Smith G, Craig JC (2003) Antibiotics and surgery for vesicoureteric reflux: a meta-analysis of randomised controlled trials. Arch Dis Child 88:688–694
Chertin B, Puri P (2002) Endoscopic management of vesicoureteral reflux: does it stand the test of time? Eur Urol 42:598–606
Joyner BD, Atala A (1997) Endoscopic substances for the treatment of vesicoureteral reflux. Urology 50:489–494
Lendvay TS, Sorensen M, Cowan CA, Joyner BD, Mitchell MM, Grady RW (2006) The evolution of vesicoureteral reflux management in the era of dextranomer/hyaluronic acid copolymer: a pediatric health information system database study. J Urol 176:1864–1867
Molitierno JA, Scherz HC, Kirsch AJ (2008) Endoscopic treatment of vesicoureteral reflux using dextranomer hyaluronic acid copolymer. J Pediatr Urol 4:221–228
McMann LP, Scherz HC, Kirsch AJ (2007) Long-term preservation of dextranomer/hyaluronic acid copolymer implants after endoscopic treatment of vesicoureteral reflux in children: a sonographic volumetric analysis. J Urol 177:316–320 discussion 320
Benoit RM, Peele PB, Docimo SG (2006) The cost-effectiveness of dextranomer/hyaluronic acid copolymer for the management of vesicoureteral reflux. 1: substitution for surgical management. J Urol 176:1588–1592
Hsieh MH, Swana HS, Baskin LS, Meng MV (2007) Cost-utility analysis of treatment algorithms for moderate grade vesicoureteral reflux using Markov models. J Urol 177:703–709
Kobelt G, Canning DA, Hensle TW, Lackgren G (2003) The cost-effectiveness of endoscopic injection of dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol 169:1480–1484
Thomson Healthcare, Solucient LLC Web Site. http://www.solucient.com/aboutus/aboutus.shtml. Accessed 6 Jan 2009
United States Health Care Financing Administration (2008) The International classification of diseases, 9th revision, clinical modification: ICD-9-CM. US Dept. of Health and Human Services, Public Health Service, US G.P.O., Washington, DC
American Medical Association (2008) Current procedural terminology: CPT. American Medical Association, Chicago, p 748
Personal communication: Regional representative for Q-Med Scandinavia/Oceana Therapeutics
Benoit RM, Peele PB, Cannon GM Jr, Docimo SG (2006) The cost-effectiveness of dextranomer/hyaluronic acid copolymer for the management of vesicoureteral reflux. 2. Reflux correction at the time of diagnosis as a substitute for traditional management. J Urol 176:2649–2653
Saperston K, Smith J, Putman S, Matern R, Foot L, Wallis C, deVries C, Snow B, Cartwright P (2008) Endoscopic subureteral injection is not less expensive than outpatient open reimplantation for unilateral vesicoureteral reflux. J Urol 180:1626–1629 (discussion 1629–1630)
Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz HC (2004) The modified sting procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol 171:2413–2416
Chand DH, Rhoades T, Poe SA, Kraus S, Strife CF (2003) Incidence and severity of vesicoureteral reflux in children related to age, gender, race and diagnosis. J Urol 170:1548–1550
Acknowledgments
The authors would like to acknowledge and thank Michael Porter, MD, MS, for his advice and statistical expertise, and Carrie Wachob for her assistance generating the figures.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sorensen, M.D., Koyle, M.A., Cowan, C.A. et al. Injection volumes of dextranomer/hyaluronic acid are increasing in the endoscopic management of vesicoureteral reflux. Pediatr Surg Int 26, 509–513 (2010). https://doi.org/10.1007/s00383-010-2558-9
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-010-2558-9